CEO’s Comment:
Over the past years, INAMED has gone international: We expanded our Europe-based respiratory technologies contract research organization to further strengthen our core services and to establish new collaborations. We now offer a broad range of services including:
- In-vitro characterization of devices and drugs
- Conducting clinical trials phase I to phase IIa in our well equipped clinical unit
- Conducting clinical trials from phase II to phase IV globally
- Specialized clinical trials, such as lung deposition or mucociliary clearance trials
- Inhalation consultations
The Unique INAMED Model
INAMED goes "respiratory".
By remaining true to our original strategy for INAMED, we have assembled a group of educated professionals in both our in-vitro teams and our clinical groups – experts our customers expect from a renowned research organization. The specialties our respiratory experts bring to the table form a one-of-a-kind combination not found at any other such organization in the world.
True experts never stop learning: Continuous training ensures that our staff can be immediately integrated into particular project teams. Our customers can expect individual, customized service from a streamlined, contract research organization able to handle ever-greater quality standards and always prepared to meet deadlines and keeps costs within a budget.
New projects are quickly integrated and adapted to the international standards and the INAMED quality system. Because our organization is a flat hierarchy, decision-making paths are shortened and an INAMED-wide, goal-oriented attitude is fostered.
INAMED’s expansion and our continued success in the CRO world are result of the enthusiastic, selfless daily work of our colleagues and the support and confidence of our partners.
Our aim is clear: INAMED’s goal is to provide the excellent service required to bring our customer’s new devices and/or compounds to the market as quickly and cost-effectively as possible. The INAMED model is the cornerstone of our work and has proven to be so successful that it will be applied to all new services we add to our portfolio.
The Future
INAMED’s future challenges are truly exciting. These include new service launches, primarily in the area of our in-vitro investigations, cooperation with sponsors from around the world and the conducting of respiratory clinical trials from phase I to phase IV on a local and global level.
In the in-vitro area, INAMED offers an improved and simplified investigation of mucociliary clearance. Due to this technology we can generate an even better standard of data.
For our clinical unit we are continuing our efforts to further broaden our services for phase I and IIa (POC) trials
Due to cooperations with excellent partners, INAMED provides full clinical service for phase II - IV trials on a global level.
The fact that more and more new compounds for local and systemic inhalation therapies are being developed means a wide variety of exciting new business opportunities. Pharmaceutical, biotech, device and medical gas companies each have a number of products in their respiratory pipelines, and INAMED is just the partner to support them and shorten the process to market approval.
The INAMED name is synonymous with expertise, know-how, quality and professionalism. We continue our efforts to become the world’s leading respiratory CRO, best able to meet the world’s project needs and challenges.
Matthias Heil, PhD
CEO of Inamed GmbH
Lung Deposition
A key parameter for an effective inhalation device
Only a small amount of inhaled aerosol reaches those regions of the respiratory tract where it is needed. We characterize the effects of your formulation, of your device, and of your patient’s breathing patterns on drug deposition in the respiratory tract. Deposition data will help to optimize your device in the early phase of development. Likewise, to determine the dose of your drug that does reach the lungs, deposition trials...